The MEK-ERK-Egr-1 axis and its regulation in cardiovascular disease
This article reviews recent progress on the MEK-ERK-Egr-1 cascade, notably regulation in conjunction with factors and agents such as TET2, TRIB2, MIAT, SphK1, cAMP, teneligliptin, cholinergic drugs, red wine and flavonoids, wogonin, febuxostat, docosahexaenoic acid and AT1R blockade. Such insights should provide new opportunity for therapeutic intervention in CVD.PMID:37734428 | DOI:10.1016/j.vph.2023.107232 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Levon M Khachigian Source Type: research
The MEK-ERK-Egr-1 axis and its regulation in cardiovascular disease
This article reviews recent progress on the MEK-ERK-Egr-1 cascade, notably regulation in conjunction with factors and agents such as TET2, TRIB2, MIAT, SphK1, cAMP, teneligliptin, cholinergic drugs, red wine and flavonoids, wogonin, febuxostat, docosahexaenoic acid and AT1R blockade. Such insights should provide new opportunity for therapeutic intervention in CVD.PMID:37734428 | DOI:10.1016/j.vph.2023.107232 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Levon M Khachigian Source Type: research
Heterogeneous vasomotor responses in segments from G öttingen Minipigs coronary, cerebral, and mesenteric artery: A comparative study
In conclusion, the vasomotor responses of isolated coronary, cerebral, and mesenteric arteries to selected agonists of endothelial, sympathetic, parasympathetic, and sensory pathways are different and the phenotypes are similar to sporadic human findings.PMID:37730143 | DOI:10.1016/j.vph.2023.107231 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - September 20, 2023 Category: Drugs & Pharmacology Authors: Anette Sams Kristian Agmund Haanes Anja Holm Spyridoula Kazantzi Lars Friis Mikkelsen Lars Edvinsson Susan Brain Majid Sheykhzade Source Type: research
Heterogeneous vasomotor responses in segments from G öttingen Minipigs coronary, cerebral, and mesenteric artery: A comparative study
In conclusion, the vasomotor responses of isolated coronary, cerebral, and mesenteric arteries to selected agonists of endothelial, sympathetic, parasympathetic, and sensory pathways are different and the phenotypes are similar to sporadic human findings.PMID:37730143 | DOI:10.1016/j.vph.2023.107231 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - September 20, 2023 Category: Drugs & Pharmacology Authors: Anette Sams Kristian Agmund Haanes Anja Holm Spyridoula Kazantzi Lars Friis Mikkelsen Lars Edvinsson Susan Brain Majid Sheykhzade Source Type: research
Optimising antithrombotic therapy after ACS and PCI
Vascul Pharmacol. 2023 Sep 15:107228. doi: 10.1016/j.vph.2023.107228. Online ahead of print.ABSTRACTDual antiplatelet therapy, combining aspirin with a platelet P2Y12 receptor inhibitor, is the standard treatment for acute coronary syndrome patients undergoing percutaneous coronary intervention. The optimal type and duration of dual antiplatelet therapy depend on the patient's risk for ischemic and hemorrhagic complications. De-escalation strategies, such as switching to a less potent P2Y12 inhibitor, reducing the dose, or discontinuing one of the antiplatelet agents, may be suitable for high-risk bleeding patients with lo...
Source: Vascular Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Davide Capodanno Source Type: research
Optimising antithrombotic therapy after ACS and PCI
Vascul Pharmacol. 2023 Sep 15:107228. doi: 10.1016/j.vph.2023.107228. Online ahead of print.ABSTRACTDual antiplatelet therapy, combining aspirin with a platelet P2Y12 receptor inhibitor, is the standard treatment for acute coronary syndrome patients undergoing percutaneous coronary intervention. The optimal type and duration of dual antiplatelet therapy depend on the patient's risk for ischemic and hemorrhagic complications. De-escalation strategies, such as switching to a less potent P2Y12 inhibitor, reducing the dose, or discontinuing one of the antiplatelet agents, may be suitable for high-risk bleeding patients with lo...
Source: Vascular Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Davide Capodanno Source Type: research
Optimising antithrombotic therapy after ACS and PCI
Vascul Pharmacol. 2023 Sep 15:107228. doi: 10.1016/j.vph.2023.107228. Online ahead of print.ABSTRACTDual antiplatelet therapy, combining aspirin with a platelet P2Y12 receptor inhibitor, is the standard treatment for acute coronary syndrome patients undergoing percutaneous coronary intervention. The optimal type and duration of dual antiplatelet therapy depend on the patient's risk for ischemic and hemorrhagic complications. De-escalation strategies, such as switching to a less potent P2Y12 inhibitor, reducing the dose, or discontinuing one of the antiplatelet agents, may be suitable for high-risk bleeding patients with lo...
Source: Vascular Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Davide Capodanno Source Type: research
Emerging therapies in dyslipidaemias
Vascul Pharmacol. 2023 Sep 14:107229. doi: 10.1016/j.vph.2023.107229. Online ahead of print.ABSTRACTSeveral observations have shown that elevated levels of low-density lipoprotein cholesterol (LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for reducing cardiovascular risk, with a continuous linear correlation between LDL-C reduction and cardiovascular benefit. Based on these observations, current guidelines have further lowered LDL-C goals and call for the use of more effective therapeutic interventions. In addition to statins, ezetimibe and the monoclonal antibodies targeting PCSK9, several...
Source: Vascular Pharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Alberico L Catapano Source Type: research
Emerging therapies in dyslipidaemias
Vascul Pharmacol. 2023 Sep 14:107229. doi: 10.1016/j.vph.2023.107229. Online ahead of print.ABSTRACTSeveral observations have shown that elevated levels of low-density lipoprotein cholesterol (LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for reducing cardiovascular risk, with a continuous linear correlation between LDL-C reduction and cardiovascular benefit. Based on these observations, current guidelines have further lowered LDL-C goals and call for the use of more effective therapeutic interventions. In addition to statins, ezetimibe and the monoclonal antibodies targeting PCSK9, several...
Source: Vascular Pharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Alberico L Catapano Source Type: research
MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension
Vascul Pharmacol. 2023 Sep 10;153:107216. doi: 10.1016/j.vph.2023.107216. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) is a complex and progressive disease characterized by pulmonary arterial remodeling. Despite that current combination therapy has shown improvement in morbidity and mortality, a better deciphering of the underlying pathological mechanisms and novel therapeutic targets is urgently needed to combat PAH. MicroRNA, the critical element in post-transcription mechanisms, mediates cellular functions mainly by tuning downstream target gene expression. Meanwhile, upstream regulators can regul...
Source: Vascular Pharmacology - September 12, 2023 Category: Drugs & Pharmacology Authors: Yang-Zhi-Ge He Yi-Xuan Wang Jing-Si Ma Ruo-Nan Li Jia Wang Tian-Yu Lian Yu-Ping Zhou Hao-Pu Yang Kai Sun Zhi-Cheng Jing Source Type: research
MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension
Vascul Pharmacol. 2023 Sep 10;153:107216. doi: 10.1016/j.vph.2023.107216. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) is a complex and progressive disease characterized by pulmonary arterial remodeling. Despite that current combination therapy has shown improvement in morbidity and mortality, a better deciphering of the underlying pathological mechanisms and novel therapeutic targets is urgently needed to combat PAH. MicroRNA, the critical element in post-transcription mechanisms, mediates cellular functions mainly by tuning downstream target gene expression. Meanwhile, upstream regulators can regul...
Source: Vascular Pharmacology - September 12, 2023 Category: Drugs & Pharmacology Authors: Yang-Zhi-Ge He Yi-Xuan Wang Jing-Si Ma Ruo-Nan Li Jia Wang Tian-Yu Lian Yu-Ping Zhou Hao-Pu Yang Kai Sun Zhi-Cheng Jing Source Type: research
MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension
Vascul Pharmacol. 2023 Sep 10:107216. doi: 10.1016/j.vph.2023.107216. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) is a complex and progressive disease characterized by pulmonary arterial remodeling. Despite that current combination therapy has shown improvement in morbidity and mortality, a better deciphering of the underlying pathological mechanisms and novel therapeutic targets is urgently needed to combat PAH. MicroRNA, the critical element in post-transcription mechanisms, mediates cellular functions mainly by tuning downstream target gene expression. Meanwhile, upstream regulators can regulate ...
Source: Vascular Pharmacology - September 12, 2023 Category: Drugs & Pharmacology Authors: Yang-Zhi-Ge He Yi-Xuan Wang Jing-Si Ma Ruo-Nan Li Jia Wang Tian-Yu Lian Yu-Ping Zhou Hao-Pu Yang Kai Sun Zhi-Cheng Jing Source Type: research
MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension
Vascul Pharmacol. 2023 Sep 10:107216. doi: 10.1016/j.vph.2023.107216. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) is a complex and progressive disease characterized by pulmonary arterial remodeling. Despite that current combination therapy has shown improvement in morbidity and mortality, a better deciphering of the underlying pathological mechanisms and novel therapeutic targets is urgently needed to combat PAH. MicroRNA, the critical element in post-transcription mechanisms, mediates cellular functions mainly by tuning downstream target gene expression. Meanwhile, upstream regulators can regulate ...
Source: Vascular Pharmacology - September 12, 2023 Category: Drugs & Pharmacology Authors: Yang-Zhi-Ge He Yi-Xuan Wang Jing-Si Ma Ruo-Nan Li Jia Wang Tian-Yu Lian Yu-Ping Zhou Hao-Pu Yang Kai Sun Zhi-Cheng Jing Source Type: research
Antineoplastic drugs inducing cardiac and vascular toxicity - An update
Vascul Pharmacol. 2023 Sep 7;153:107223. doi: 10.1016/j.vph.2023.107223. Online ahead of print.ABSTRACTWith the improvement in cancer prognosis due to advances in antitumor therapeutic protocols and new targeted and immunotherapies, we are witnessing a growing increase in survival, however, at the same timeincrease in morbidity among cancer survivors as a consequences of the increased cardiovascular adverse effects of antineoplastic drugs. Common cardiovascular complications of antineoplastic therapies may include cardiac complications such as arrhythmias, myocardial ischemia, left ventricular dysfunction culminating in he...
Source: Vascular Pharmacology - September 7, 2023 Category: Drugs & Pharmacology Authors: Serena Barachini Sandra Ghelardoni Zolt án V Varga Radwa A Mehanna Maria Magdalena Montt-Guevara P éter Ferdinandy Rosalinda Madonna Source Type: research
Antineoplastic drugs inducing cardiac and vascular toxicity - An update
Vascul Pharmacol. 2023 Sep 7;153:107223. doi: 10.1016/j.vph.2023.107223. Online ahead of print.ABSTRACTWith the improvement in cancer prognosis due to advances in antitumor therapeutic protocols and new targeted and immunotherapies, we are witnessing a growing increase in survival, however, at the same timeincrease in morbidity among cancer survivors as a consequences of the increased cardiovascular adverse effects of antineoplastic drugs. Common cardiovascular complications of antineoplastic therapies may include cardiac complications such as arrhythmias, myocardial ischemia, left ventricular dysfunction culminating in he...
Source: Vascular Pharmacology - September 7, 2023 Category: Drugs & Pharmacology Authors: Serena Barachini Sandra Ghelardoni Zolt án V Varga Radwa A Mehanna Maria Magdalena Montt-Guevara P éter Ferdinandy Rosalinda Madonna Source Type: research
